Global Travel Media » Blog Archive Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant | Global Travel Media

Home » Coronavirus (Covid-19) » Currently Reading:

[sam id="86" codes="true"]

Acumen Diagnostics’ PCR capabilities to tackle Omicron COVID-19 variant

December 6, 2021 Coronavirus (Covid-19) No Comments

Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics” or the “Company”), a 51% owned subsidiary of Q&M Dental Group (Singapore) and 49% owned by Aoxin Q&M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction (“PCR”) test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.

Dr Ong Siew Hwa, Executive Director of Aoxin Q&M Dental and Chief Executive Officer & Chief Scientist of Acumen Diagnostics said, “As the COVID-19 threat continues to evolve with the emergence of a potentially more transmissible variant, Omicron, highly-accurate and cost-effective COVID-19 testing becomes even more important to detect and help curb the spread of the virus.

With PCR tests remaining the gold standard to detect COVID-19, Acumen Diagnostics remains well-positioned to help Singapore tackle this new challenge posed by the virus, with our effective and affordable PCR test kits that are equipped to detect COVID-19 positive cases infected with Delta and Omicron, as well as our laboratory testing capabilities that can run 7000 tests daily. We will continue to contribute to national COVID-19 testing efforts to support Singapore’s safe and sustainable re-opening.”

In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company’s proprietary PCR test kits are able to detect COVID-19 positive cases infected with the Omicron variant as well.

The Acu-Corona 2.0 PCR test targets two COVID-19 genes – RdRp and E, while the Acu-Corona Duplex PCR test targets the E gene and S gene. The portion of the S gene targeted by the Acu-Corona Duplex PCR test does not contain any of the 32 mutations that occurred in the Omicron variant, hence it can detect the Omicron variant without any loss of sensitivity.

This proprietary technology used in PCR test kits and laboratory testing is developed and owned by Acumen Diagnostics. Being locally manufactured, the Company’s test kits can be deployed quickly and are more cost-effective and allow for greater self-sufficiency, compared to that of its peers imported from overseas.

Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process 7000 COVID-19 diagnostics tests daily.

0 0 votes
Article Rating

0 Comments
Inline Feedbacks
View all comments

Comment on this Article:







Subscribe To Receive Our Daily Global Travel Media Newsletter

The FIRST Australian-based news alert is to be delivered every Morning to your Inbox before you arrive at your desk.

Sponsor / Partners

Luxury Traveller by Robert La Bua – SideBar  Position -1
Top 25 Restaurants

 

ADVERTISEMENTS

Back To School Sale! Up to 50% OFF – Huawei Tower Banner

ADVERTISEMENTS

ADVERTISEMENTS

ADVERTISEMENTS

ADVERTISEMENTS

TravelManagers Tower Banner Nov

GLOBAL TRAVEL MEDIA VIDEOS

 

 

 

TravelManagers Tower 2 300x600px

Advertisments

TravelManagers NOV Leader / Footer Banner
Global Travel Media
0
Would love your thoughts, please comment.x
()
x
%d bloggers like this:
Global Travel Media
0
Would love your thoughts, please comment.x
()
x
%d bloggers like this:
sitemap